Deutsche Bank (DB) Analysts Reiterate a "Buy" Rating on Medtronic, Inc. (MDT)
Wednesday, June 29, 2021 12:10 PM

Related Stories

Equities research analysts at Deutsche Bank (NYSE: DB) reiterated a "buy" rating on shares of Medtronic, Inc. (NYSE: MDT) in a research note to investors on Wednesday. The analysts currently have a $45.00 price target on the stock.

Separately, analysts at Morgan Stanley (NYSE: MS) reiterated an "equal weight" rating on shares of Medtronic, Inc. in a research note to investors on Wednesday. Also, analysts at Morgan Keegan initiated coverage on shares of Medtronic, Inc. in a research note to investors on Friday, June 17th. They set a "market perform" rating and a $43.00 price target on the stock.

Shares of Medtronic, Inc. traded down 1.49% during mid-day trading on Thursday, hitting $38.43. Medtronic, Inc. has a 52 week low of $30.80 and a 52 week high of $43.33. The stock's 50-day moving average is $40.03 and its 200-day moving average is $39.1. The company has a market cap of $41.126 billion and a price-to-earnings ratio of 13.64.

Medtronic, Inc. last announced its quarterly results on Tuesday, May 24th. The company reported $0.90 earnings per share (EPS) for the previous quarter, missing the Thomson Reuters consensus estimate of $0.93 EPS by $0.03. The company’s quarterly revenue was up 2.4% on a year-over-year basis. On average, analysts predict that Medtronic, Inc. will post $0.83 EPS next quarter.

Medtronic, Inc. (Medtronic) is a medical technology company. The Company is engaged in research, design, manufacture and sale of products to alleviate pain, restore health and extend life. It manufactures and sells device-based medical therapies. It operates in seven segments: Cardiac Rhythm Disease Management, Spinal, CardioVascular, Neuromodulation, Diabetes, Surgical Technologies and Physio-Control. Its primary customers include hospitals, clinics, third party healthcare providers, distributors and other institutions, including governmental healthcare programs and group purchasing organizations. In April 2010, the Company completed the acquisition of Invatec, S.p.A., a developer of medical technologies for the interventional treatment of cardiovascular disease. In November 2010, the Company acquired Osteotech.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.